Evidence map›Paper›PMID 37218522›Full record

ArticleThe Analyst2023

Leveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer.

Chalapathi Charan Gajjela, Matthew Brun, Rupali Mankar, Sara Corvigno, Noah Kennedy, Yanping Zhong, Jinsong Liu, Anil K Sood, David Mayerich, Sebastian Berisha and 1 more

Open access · greenAbstract read
In one paragraph

Article in The Analyst, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Chalapathi Charan GajjelaUniversity of Houston, 4226 Martin Luther King Boulevard, N308 Engineering Building 1, Houston, TX, 77584, USA. rkreddy@uh.edu.
Matthew BrunRice University, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9615-5175
Rupali MankarUniversity of Houston, 4226 Martin Luther King Boulevard, N308 Engineering Building 1, Houston, TX, 77584, USA. rkreddy@uh.edu.
Sara CorvignoThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Noah KennedyMilwaukee School of Engineering, Milwaukee, WI, USA.
Yanping ZhongThe First Hospital of Jilin University, Changchun, Jilin, 130021, China.
Jinsong LiuThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Anil K SoodThe University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
David MayerichUniversity of Houston, 4226 Martin Luther King Boulevard, N308 Engineering Building 1, Houston, TX, 77584, USA. rkreddy@uh.edu.ORCID http://orcid.org/0000-0002-3949-6133
Sebastian BerishaMilwaukee School of Engineering, Milwaukee, WI, USA.
Rohith ReddyUniversity of Houston, 4226 Martin Luther King Boulevard, N308 Engineering Building 1, Houston, TX, 77584, USA. rkreddy@uh.edu.ORCID http://orcid.org/0000-0002-4403-5614
The University of Texas MD Anderson Cancer Center · USUniversity of Houston · USMilwaukee School of Engineering · USRice University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
TRAINING PROGRAM IN COMPUTATIONAL BIOLOGY AND MEDICINET15LM007093 · NLM · RICE UNIVERSITY · PI Lydia E. Kavraki · 1992 to 2026
$20.8M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, SOOD, ANIL K · 2017 to 2021
$7.9M
Structural and Molecular Phenotyping of Embryonic Development through Multi-Modal Optical ImagingR01HL146745 · NHLBI · UNIVERSITY OF HOUSTON · PI MAYERICH, DAVID · 2019 to 2023
$3.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA217685NHLBI NIH HHS R01 HL146745NLM NIH HHS T15 LM007093
6 · The paper itself

Abstract

Mid-infrared spectroscopic imaging (MIRSI) is an emerging class of label-free techniques being leveraged for digital histopathology. Modern histopathologic identification of ovarian cancer involves tissue staining followed by morphological pattern recognition. This process is time-consuming and subjective and requires extensive expertise. This paper presents the first label-free, quantitative, and automated histological recognition of ovarian tissue subtypes using a new MIRSI technique. This optical photothermal infrared (O-PTIR) imaging technique provides a 10× enhancement in spatial resolution relative to prior instruments. It enables sub-cellular spectroscopic investigation of tissue at biochemically important fingerprint wavelengths. We demonstrate that the enhanced resolution of sub-cellular features, combined with spectroscopic information, enables reliable classification of ovarian cell subtypes achieving a classification accuracy of 0.98. Moreover, we present a statistically robust analysis from 78 patient samples with over 60 million data points. We show that sub-cellular resolution from five wavenumbers is sufficient to outperform state-of-the-art diffraction-limited techniques with up to 235 wavenumbers. We also propose two quantitative biomarkers based on the relative quantities of epithelia and stroma that exhibit efficacy in early cancer diagnosis. This paper demonstrates that combining deep learning with intrinsic biochemical MIRSI measurements enables quantitative evaluation of cancerous tissue, improving the rigor and reproducibility of histopathology.

Indexed as

Deep LearningOvarian NeoplasmsDiagnostic ImagingFemaleHumansReproducibility of ResultsSpectrophotometry, Infrared

Identifiers

PMID37218522
PMCPMC12616426
OpenAlexW4377564201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.